Relmada Therapeutics Q4 net loss narrows as expenses decline

Relmada Therapeutics

19/03/2026 20:20

Overview

US biotech firm's Q4 net loss narrowed yr/yr as R&D and G&A expenses declined

Relmada completed $160 mln PIPE financing, expects cash to fund operations through 2029

Outlook

Relmada expects cash resources to fund operations through 2029, including NDV-01 RESCUE program

Result Drivers

LOWER R&D SPENDING - R&D expenses fell yr/yr due to completion of two Phase 3 trials for REL-1017, partially offset by increased costs for NDV-01 and sepranolone

REDUCED G&A COSTS - General and administrative expenses declined yr/yr, mainly due to lower stock-based compensation and professional fees, partially offset by higher personnel costs

Company press release: ID:nGNXJwvZy

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 EPS
-$0.27
Q4 Net Income
-$19.90 mln


Analyst Coverage

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy."

Wall Street's median 12-month price target for Relmada Therapeutics Inc is $10.00, about 61% above its March 18 closing price of $6.21

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)